STOCK TITAN
  1. Home
  2. News
  3. ATRA

Atara Biotherapeutics Inc - ATRA STOCK NEWS

Welcome to our dedicated news page for Atara Biotherapeutics (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atara Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atara Biotherapeutics's position in the market.

News
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Atara Biotherapeutics, Inc. granted 3,750 restricted stock units to a new employee under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
News
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Rhea-AI Summary
Atara Biotherapeutics (ATRA) reported positive pre-BLA meeting for tab-cel, expanding into autoimmune diseases. Financially, they received $27 million upfront from Pierre Fabre, potentially $640 million more, with key pipeline readouts funded till 2027. ATA3219 lupus nephritis study planned with initial data in H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
earnings
-
News
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Rhea-AI Summary
Atara Biotherapeutics, Inc. receives second IND clearance for ATA3219, a CAR T-cell therapy for lupus nephritis. Clinical data expected in 2024 and 2025. The therapy aims to address unmet needs in autoimmune diseases, offering potentially curative off-the-shelf treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
clinical trial
News
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) announces participation in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference. Pascal Touchon, President and CEO, to present on March 6, 2024. Webcast details provided for investors and media.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
-
News
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Rhea-AI Summary
Atara Biotherapeutics submits IND for ATA3219, a novel CAR T-cell therapy targeting lupus nephritis, aiming to revolutionize treatment options for patients with autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Rhea-AI Summary
Atara Biotherapeutics and Pierre Fabre Laboratories announced the publication of pivotal Phase 3 ALLELE study data for tab-cel, an allogeneic T-cell therapy for EBV+ PTLD patients. The study showed a 51.2% objective response rate and a 23.0 month median duration of response. The U.S. BLA submission for tab-cel is on track for Q2 2024. The study met its primary endpoint, and tab-cel was well-tolerated with no reported adverse events. These results highlight the clinical value of tab-cel and its potential to address an urgent unmet medical need for patients with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.01%
Tags
clinical trial
News
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) announces a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registered direct offering to entities affiliated with an existing institutional investor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
offering
-
News
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of a partnership expansion with Pierre Fabre Laboratories for the global commercialization of tab-cel. The company's BLA for tab-cel is on track for submission in Q2 2024, following positive new data from the pivotal ALLELE study. Atara also plans to expand its next-gen allogeneic CAR-T portfolio to include autoimmune disease ATA3219. The company's strategic restructuring has extended its cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
conferences
-
News
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at 42nd Annual J.P. Morgan Healthcare Conference, showcasing its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
News
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). The transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets. Atara will receive approximately USD 27 million in cash upfront and initial inventory purchase, with the potential to receive up to a total of USD 640 million and significant double-digit tiered royalties on net sales. Atara plans to submit the BLA to the U.S. FDA for tab-cel for the treatment of post-transplant lymphoproliferative disease (PTLD) in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.49%
Tags
partnership
Stock ATRA logo
Atara Biotherapeutics Inc

Nasdaq:ATRA

ATRA Rankings

#4393 Ranked by Market Cap
#5201 Ranked by Stock Gains
N/A Ranked by Dividends

ATRA Stock Data

81.36M
90.37M
5.9%
62.91%
9.41%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
South San Francisco

About ATRA

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have